2024
・Song I, Yang J, Saito M, Hartanto T, Nakayama Y,
Ichinohe T, Fukuda S. Prebiotic inulin ameliorates
SARS-CoV-2 infection in hamsters by modulating the gut microbiome.
NPJ Sci Food. 2024 Mar
14;8(1):18.
2023
・Shibata T, Sato R, Taoka M, Saitoh SI, Komine M, Yamaguchi K, Goyama S, Motoi Y, Kitaura J, Izawa K,
Yamauchi Y, Tsukamoto Y,
Ichinohe T, Fujita E, Hiranuma R, Fukui R, Furukawa Y, Kitamura T, Takai T,
Tojo A, Ohtsuki M, Ohto U, Shimizu T, Ozawa M, Yoshida N, Isobe T, Latz
E, Mukai K, Taguchi T, Hemmi
H, Akira S, Miyake K. TLR7/8 stress response drives histiocytosis in SLC29A3 disorders.
J Exp Med. 2023
Sep 4;220(9):e20230054.
・Nagai M, Moriyama M, Ishii C, Mori H, Watanabe H, Nakahara T, Yamada T,
Ishikawa D, Ishikawa T,
Hirayama A, Kimura I, Nagahara A, Naito T*, Fukuda S*,
Ichinohe T*. High body temperature increases
gut microbiota-dependent host resistance to influenza A virus and SARS-CoV-2
infection.
Nat Commun.
2023 Jun 30;14(1):3863. [
Link]
・Tatsuma T, Nakakido M,
Ichinohe T, Kuroiwa Y, Tomioka K, Liu C, Miyamae N, Onuki T, Tsumoto K,
Hashimoto K, Wakihara T. Inactivation and spike protein denaturation of novel coronavirus variants by
CuxO/TiO2 nano-photocatalysts.
Sci Rep. 2023 Mar 10;13(1):4033.
2021
・ Nagai M, Moriyama M,
Ichinohe T*. Oral Bacteria Combined with an Intranasal Vaccine Protect from
Influenza A Virus and SARS-CoV-2 Infection.
mBio. 2021 Aug 17;12(4):e01598-21.[
Link]
・Liu K, Sato R, Shibata T, Hiranuma R, Reuter T, Fukui R, Zhang Y,
Ichinohe T, Ozawa M, Yoshida N, Latz
E, Miyake K. Skewed endosomal RNA responses from TLR7 to TLR3 in RNase T2-deficient macrophages.
Int Immunol. 2021 Jun 23:dxab033. doi: 10.1093/intimm/dxab033.
2020
・Yamamoto M,
Ichinohe T, Watanabe A, Kobayashi A, Zhang R, Song J, Kawaguchi Y, Matsuda Z, Inoue
JI.
The Antimalarial Compound Atovaquone Inhibits Zika and Dengue Virus Infection
by Blocking E Protein-
Mediated Membrane Fusion.
Viruses. 2020 Dec 21;12(12):1475.
・Moriyama M, Nagai M, Maruzuru Y, Koshiba T, Kawaguchi Y,
Ichinohe T*. Influenza virus-induced oxidized DNA activates inflammasomes.
iScience 2020 Jun 14;23(7):101270. [
Link]
2019
・Negishi H, Endo N, Nakajima Y, Nishiyama T, Tabunoki Y, Nishio J, Koshiba
R, Matsuda A, Matsuki K,
Okamura T, Negishi-Koga T,
Ichinohe T, Takemura S, Ishiwata H, Iemura SI, Natsume T, Abe T, Kiyonari
H, Doi T, Hangai S, Yanai H, Fujio K, Yamamoto K, Taniguchi T. Identification
of U11snRNA as an
endogenous agonist of TLR7-mediated immune pathogenesis.
Proc Natl Acad Sci U S A. 2019 Nov
19;116(47):23653-23661.
・Moriyama M, Koshiba T,
Ichinohe T*. Influenza A virus M2 protein triggers mitochondrial DNA-mediated antiviral
immune responses.
Nat Commun. 2019 Oct 11;10(1):4624. [
Link]
・Moriyama M,
Ichinohe T*. High ambient temperature dampens adaptive immune responses to influenza
A virus infection.
Proc Natl Acad Sci U S A. 2019 Feb 19;116(8):3118-3125 [
Link]
・Chen IY, Moriyama M, Chang MF,
Ichinohe T*. Severe Acute Respiratory Syndrome Coronavirus Viroporin 3a Activates
the NLRP3 Inflammasome.
Front Microbiol. 2019 Jan 29;10:50. [
Link]
・Furusho K, Shibata T, Sato R, Fukui R, Motoi Y, Zhang Y, Saitoh SI,
Ichinohe T, Moriyama M, Nakamura S, Miyake K. Cytidine deaminase enables Toll-like
receptor 8 activation by cytidine or its analogs.
Int
Immunol. 2019 Mar 5;31(3):167-173.
2018
・Moriyama M, Igarashi M, Koshiba T, Irie T, Takada A,
Ichinohe T*. Two conserved amino acids
within the NSs of SFTS phlebovirus are essential for anti-interferon activity.
J Virol. 2018 Sep 12;92(19). pii: e00706-18. [
Link]
・Maruzuru Y,
Ichinohe T, Sato R, Miyake K, Okano T, Suzuki T, Koshiba T, Koyanagi N, Tsuda S,
Watanabe
M, Arii J, Kato A, Kawaguchi Y. Herpes Simplex VIrus 1 VP22 Inhibits AIM2-dependent Inflammasome
Activation to Enable Efficient Viral Replication.
Cell Host & Microbe. Feb 14;23(2):254-265.
・Walenna NF, Kurihara Y, Chou B, Ishii K, Soejima T, Itoh R, Shimizu A,
Ichinohe T, Hiromatsu K.
Chlamydia pneumoniae exploits adipocyte lipid chaperone FABP4 to facilitate
fat mobilization and
intracellular growth in murine adipocytes.
Biochem Biophys Res Commun. Jan 1;495(1):353-359.
2017
・Saitoh SI, Abe F, Kanno A, Tanimura N, Mori Saitoh Y, Fukui R, Shibata
T, Sato K,
Ichinohe T,
Hayashi M, Kubota K, Kozuka-Hata H, Oyama M, Kikko Y, Katada T, Kontani
K, Miyake K.
TLR7 mediated viral recognition results in focal type I interferon secretion
by dendritic cells.
Nat Commun. 2017 Nov 17;8(1):1592.
・Moriyama M, Takeyama H, Hasegawa H,
Ichinohe T*. Induction of lung CD8+ T cell responses by
consecutive inoculations of a poly(I:C) infleunza vaccine.
Vaccine. 2017 Dec 4;35(48 Pt B):6620-6626.
・Koyanagi N, Imai T, Shindo K, Sato A, Fujii W,
Ichinohe T, Takemura N, Kakuta S, Uematsu S, Kiyono H,
Maruzuru Y, Arii J, Kata A, Kawaguchi Y. Herpes simplex virus-1 evasion
of CD8+ T cell accumulation
contributes to viral encephalitis.
J Clin Invest. 2017 Oct 2;127(10):3784-3795.
・Moriyama M, Chino S,
Ichinohe T*. Consecutive inoculations of influenza virus vaccine and poly(I:C)
protects mice against homologous and heterologous virus challenge.
Vaccine. 2017 Feb 15;35(7):1001-1007.
2016
・Moriyama M, Chen IY, Kawaguchi A, Koshiba T, Nagata K, Takeyama H, Hasegawa,
H,
Ichinohe T*.
The RNA- and TRIM25-binding domains of infleunza virus NS1 protein are
essential for suppression of
NLRP3 inflammasome-mediated IL-1β secretion.
J Virol. 2016 Mar 28;90(8):4105-14. [
Link]
2015 ・Chen IY,
Ichinohe T*. Response of host inflammasomes to viral infection.
Trends Microbiol. 2015 Jan;23(1):55-63.
2014
・Yoshizumi T,
Ichinohe T, Sasaki O Otera H, Kawabata SI, Mihara K, Koshiba T. Influenza A
virus protein PB1-F2 translocates into mitochondria via Tom40 channels
and impairs innate
immunity.
Nat Commun. 2014 Aug 20;5:4713. doi: 10.1038/ncomms5713
・Yamazaki T,
Ichinohe T*. Inflammasomes in antiviral immunity: clues for influenza vaccine
development.
Clin Exp Vaccines Res. 2014 Jan;3(1):5-11.
2013
・
Ichinohe T*, Yamazaki T, Koshiba T, Yanagi Y. Mitochondrial protein mitofusin 2 is
required for
NLRP3 inflammsome activation after RNA virus infection.
Proc Natl Acad Sci U S A. 2013 Oct
29;110(44):17963-8. [
Link]
・Pang IK,
Ichinohe T, Iwasaki A. IL-1R signaling in dendritic cells replaces pattern-recognition
receptors in promoting CD8(+) T cell responses to influenza A virus.
Nat Immunol. 2013 Jan 13;14(3):246-53.
2012
・Ito M, Yanagi Y,
Ichinohe T*. Encephalomyocarditis virus viroporin 2B activates NLRP3
inflammasome.
PLoS Pathog. 2012 Aug;8(8):e1002857. [
Link]
2011
・Komune N,
Ichinohe T*, Ito M, Yanagi Y. Measles virus V protein inhibits NLRP3
inflammsome-mediated interleukin-1β secretion.
J Virol. 2011 Dec;85(24):13019-26.
・
Ichinohe T, Pang IK, Kumamoto Y, Peaper D, Ho JH, Murray TS, Iwasaki A. Microbiota
regulates immune defense against respiratory tract influenza A virus infection.
Proc Natl Acad Sci U S A. 2011 March 29;108(13):5354-9. [
Link]
・
Ichinohe T*, Yanagi Y. Recognition of viruses by inflammasomes.
Fukuoka Igaku Zasshi.
2011 Feb;102(2):21-30. Review.
2010・
Ichinohe T*. Respective roles of TLR, RIG-I and NLRP3 in influenza virus infection
and
immunity: impact on vaccine design.
Expert Rev Vaccines. 2010 Nov;9(11):1315-24. Review.
・
Ichinohe T, Ainai A, Ami Y, Nagata N, Iwata N, Kawaguchi A, Suzaki Y, Odagiri T, Tashiro M,
Takahashi H, Strayer DR, Carter WA, Chiba J, Tamura S, Sata T, Kurata
T, Hasegawa H.
Intranasal administration of adjuvant-combined vaccine protects monkeys
from challenge with
the highly pathogenic influenza A H5N1 virus.
J Med Virol. 2010 Oct;82(10):1754-61.
・
Ichinohe T, Pang IK, Iwasaki A. Influenza virus activates inflammasomes via its intracellular
M2 ion channel.
Nat Immunol. 2010 May;11(5):404-10. [
Link]
・Ainai A,
Ichinohe T, Tamura S, Kurata T, Sata T, Tashiro M, Hasegawa H. Zymosan enhances
the mucosal adjuvant activity of poly(I :C) in a nasal influenza vaccine.
J Med Virol. 2010
Mar;82(3):476-84.
・
Ichinohe T, Ainai A, Nakamura T, Akiyama Y, Maeyama J, Odagiri T, Tashiro M, Takahashi
H,
Sawa H, Tamura S, Chiba J, Kurata T, Sata T, Hasegawa H. Induction of
cross-protective
immunity against influenza A virus H5N1 by an intranasal vaccine with
extracts of mushroom
mycelia.
J Med Virol. 2010 Jan;82(1):128-37.
2009
・
Ichinohe T*, Iwasaki A. Inflammasomes in viral infection.
Uirusu. 2009 Jun;59(1):13-21.
Review.
・
Ichinohe T, Ainai A, Tashiro M, Sata T, Hasegawa H. PolyI:polyC12U adjuvant-combined
intranasal vaccine protects mice against highly pathogenic H5N1 influenza
virus variants.
Vaccine. 2009 Oct 23;27(45):6276-9.
・Hasegawa H,
Ichinohe T, Ainai A, Tamura S, Kurata T. Development of mucosal adjuvants for
intranasalvaccine for H5N1 influenza viruses.
Ther Clin Risk Manag. 2009 Feb;5(1):125-32.
・
Ichinohe T, Lee HK, Ogura Y, Flavell R, Iwasaki A.Inflammasome recognition of influenza
virus
is essential for adaptive immune responses.
J Exp Med. 2009 Jan 16;206(1):79-87. [
Link]
2008年以前・
Ichinohe T*, Iwasaki A, Hasegawa H. Innate sensors of influenza virus: clues to developing
better intranasal vaccines.
Expert Rev Vaccines. 2008 Nov;7(9):1435-45. Review.
・Kamijuku H*, Nagata Y*, Jiang X*,
Ichinohe T*, Tashiro T, Mori K, Taniguchi M, Hase K,
Ohno H,Shimaoka T, Yonehara S, Odagiri T, Tashiro M, Sata T, Hasegawa
H, Seino KI.
Mechanism of NKT cell activation by intranasal coadministration of alpha-galactosylceramide,
which can induce cross-protection against influenza viruses.
Mucosal Immunol. 2008
May;1(3):208-18.
・
Ichinohe T, Tamura S, Kawaguchi A, Ninomiya A, Imai M, Itamura S, Odagiri T, Tashiro
M,
Takahashi H, Sawa H, Mitchell WM, Strayer DR, Carter WA, Chiba J, Kurata T, Sata T,
Hasegawa H. Cross-protection against H5N1 influenza virus infection is
afforded by intranasal
inoculation with seasonal trivalent inactivated influenza vaccine.
J Infect Dis. 2007 Nov
1;196(9):1313-20.
・
Ichinohe T, Kawaguchi A, Tamura S, Takahashi H, Sawa H, Ninomiya A, Imai M, Itamura
S,
Odagiri T, Tashiro M, Chiba J, Sata T, Kurata T, Hasegawa H. Intranasal
immunization
with H5N1 vaccine plus Poly I:Poly C12U, a Toll-like receptor agonist,
protects mice against
homologous and heterologous virus challenge.
Microbes Infect. 2007 Sep;9(11):1333-40.
・
Ichinohe T, Nagata N, Strong P, Tamura S, Takahashi H, Ninomiya A, Imai M, Odagiri
T, Tashiro
M, Sawa H, Chiba J, Kurata T, Sata T, Hasegawa H. Prophylactic effects
of chitin microparticles
on highly pathogenic H5N1 influenza virus.
J Med Virol. 2007 Jun;79(6):811-9.
・Hasegawa H,
Ichinohe T, Tamura S, Kurata T. Development of a mucosal vaccine for influenza
viruses: preparation for a potential influenza pandemic.
Expert Rev Vaccines. 2007
Apr;6(2):193-201. Review.
・Asahi-Ozaki Y, Itamura S,
Ichinohe T, Strong P, Tamura S, Takahashi H, Sawa H, Moriyama M,
Tashiro M, Sata T, Kurata T, Hasegawa H. Intranasal administration of
adjuvant-combined
recombinant influenza virus HA vaccine protects mice from the lethal H5N1 virus infection.
Microbes Infect. 2006 Oct;8(12-13):2706-14.
・Maeda M, Sawa H, Tobiume M, Tokunaga K, Hasegawa H,
Ichinohe T, Sata T, Moriyama M,
Hall WW, Kurata T, Takahashi H. Tristetraprolin inhibits HIV-1 production
by binding to genomic
RNA.
Microbes Infect. 2006 Sep;8(11):2647-56.
・
Ichinohe T, Watanabe I, Tao E, Ito S, Kawaguchi A, Tamura S, Takahashi H, Sawa H,
Moriyama M, Chiba J, Komase K, Suzuki Y, Kurata T, Sata T, Hasegawa H.
Protection against
influenza virus infection by intranasal vaccine with surf clam microparticles
(SMP) as an
adjuvant.
J Med Virol. 2006 Jul;78(7):954-63.
・Hasegawa H, Sawa H, Lewis MJ, Orba Y, Sheehy N, Yamamoto Y,
Ichinohe T,
Tsunetsugu-Yokota Y, Katano H, takahashi H, Matsuda J, Sata T, Kurata
T, Nagashima K, hall
WW. Thymus-derived leukemia-lymphoma in mice transgenic for the Tax gene
of human
T-lymphotropic virus type I.
Nat Med. 2006 Apr;12(4):466-72.
・
Ichinohe T, Watanabe I, Ito S, Fujii H, Moriyama M, Tamura S, Takahashi H, Sawa H,
Chiba J,
Kurata T, Sata T, Hasegawa H. Synthetic double-stranded RNA poly(I:C)
combined
with mucosal vaccine protects against influenza virus infection.
J Virol. 2005 Mar;79(5):2910-9.
・Hasegawa H,
Ichinohe T, Strong P, Watanabe I, Ito S, Tamura S, Takahashi H, Sawa H,
Chiba J, Kurata T, Sata T. Protection against influenza virus infection by intranasal
administration of hemagglutinin vaccine with chitin microparticles as
an adjuvant.
J Med Virol.
2005 Jan;75(1):130-6.
・Watanabe I, Ross TM, Tamura S,
Ichinohe T, Ito S, Takahashi H, Sawa H, Chiba J, Kurata T,
Sata T, Hasegawa H. Protection against influenza virus infection by intranasal administration of
C3d-fused hemagglutinin.
Vaccine. 2003 Nov 7;21(31):4532-8.